Bionano Genomics 2025 Q3 Earnings 80.8% Net Loss Reduction

Bionano Genomics (NASDAQ:BNGO) reported Q3 2025 earnings on November 14, 2025, with revenue of $7.37 million—21.3% higher than $6.07 million in Q3 2024—surpassing the $6.91 million consensus. The company reiterated full-year revenue guidance of $26–30 million and raised Q4 2025 installation targets to 25+ systems.

Revenue

Product revenue accounted for the lion’s share, contributing $6.93 million, while service and other revenue totaled $433,000. This reflects a strategic shift toward consumables and software, with 8,390 flowcells sold in Q3—a 7% year-over-year increase. The Americas (38.6%) and EMEA (49.3%) drove regional growth, supported by 7 new OGM system installations, bringing the total to 384.

Earnings/Net Income

Bionano narrowed its net loss to $8.50 million (80.8% improvement) compared to $44.25 million in Q3 2024. Earnings per share improved from a $30.92 loss to $1.59, though losses have persisted for 9 consecutive years. The reduction in operating expenses by 40% to $9.7 million underscored cost discipline.

Post-Earnings Price Action Review

A 30-day holding strategy post-earnings announcement yielded a 20.83% stock price increase, outperforming the market. Despite this, shares fell 8.13% on the day of the report and 29.67% month-to-date, reflecting mixed investor sentiment.

CEO Commentary

CEO Erik Holmlin emphasized sustainable growth through consumables and software adoption, noting “transforming pathology from analog to digital.” He highlighted 25+ OGM installations expected by year-end and momentum in Japan, where OGM addresses complex genetic challenges.

Guidance

Bionano reiterated full-year 2025 revenue guidance of $26–30 million and set Q4 2025 revenue at $7.5–7.9 million. The company also aims to secure CMS reimbursement for OGM, with preliminary payment determinations posted.

Additional News

Bionano completed a $10 million public offering in September 2025, strengthening its balance sheet. The company announced 23 new OGM system installations year-to-date and expanded into Japan, where OGM adoption is accelerating. CMS’s preliminary payment determination for OGM’s Category I CPT code also marked a regulatory milestone.